1
|
Liu B, Thompson G, Jörg M, Barnes N, Thal DM, Christopoulos A, Capuano B, Valant C, Scammells PJ. Discovery of 2-Methyl-5-(1 H-pyrazol-4-yl)pyridines and Related Heterocycles as Promising M 4 mAChR Positive Allosteric Modulators for the Treatment of Neurocognitive Disorders. J Med Chem 2024. [PMID: 39023902 DOI: 10.1021/acs.jmedchem.4c01207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/20/2024]
Abstract
The M4 muscarinic acetylcholine receptor (mAChR) is a biological target for neurocognitive disorders. Compound 1 is an ago-PAM for the M4 mAChR. Herein, we report the design, synthesis, and evaluation of novel putative M4 mAChR PAMs based on 1. These analogs were screened and then fully characterized in two functional assays (GoB protein activation and CAMYEL activation) to quantify their allosteric and ago-PAM properties against ACh. A selection of 7 M4 PAMs were assessed for their ability to modulate ACh-mediated β-arrestin recruitment and revealed 4 distinct clusters of M4 PAM activity: (1) analogs similar to 1 (24d), (2) analogs demonstrating only allosteric agonism (23d), (3) analogs with increased allosteric properties in CAMYEL activation (23b/23f and 24a/24b), and (4) analogs with a biased modulatory effect toward β-arrestin recruitment (23i). These novel M4 chemical tools disclose discrete molecular determinants, allowing further interrogation of the therapeutic roles of cAMP and β-arrestin pathways in neurocognitive disorders.
Collapse
Affiliation(s)
- Boqun Liu
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Geoff Thompson
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Manuela Jörg
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Nicholas Barnes
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - David M Thal
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
- Australian Research Council Centre for Cryo-Electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Arthur Christopoulos
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
- Australian Research Council Centre for Cryo-Electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
- Neuromedicines Discovery Centre, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Ben Capuano
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Celine Valant
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
- Australian Research Council Centre for Cryo-Electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Peter J Scammells
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| |
Collapse
|
2
|
Liu J, Huang J, Wang K, Li Y, Li C, Zhu Y, He X, Zhang Y, Zhao Y, Hu C, Xi Z, Tong M, Li Z, Gong P, Hou Y. Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer. Bioorg Med Chem 2024; 101:117609. [PMID: 38364599 DOI: 10.1016/j.bmc.2024.117609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2023] [Revised: 01/16/2024] [Accepted: 01/16/2024] [Indexed: 02/18/2024]
Abstract
In this study, we have designed, synthesized and tested three series of novel dihydropteridone derivatives possessing isoindolin-1-one or isoindoline moieties as potent inhibitors of PLK1/BRD4. Remarkably, most of the compounds showed preferable inhibitory activity against PLK1 and BRD4. Compound SC10 exhibited excellent inhibitory activity with IC50 values of 0.3 nM and 60.8 nM against PLK1 and BRD4, respectively. Meanwhile, it demonstrated significant anti-proliferative activities against three tumor-derived cell lines (MDA-MB-231 IC50 = 17.3 nM, MDA-MB-361 IC50 = 8.4 nM, and MV4-11 IC50 = 5.4 nM). Moreover, SC10 exhibited moderate rat liver microsomal stability (CLint = 21.3 µL·min-1·mg-1), acceptable pharmacokinetic profile (AUC0-t = 657 ng·h·mL-1, oral bioavailability of 21.4 %) in Sprague-Dawley rats, reduced hERG toxicity, acceptable PPB and CYP450 inhibition. Further research indicated that SC10 could induce MV4-11 cell arrest at the S phase and apoptosis in a dose-dependent manner. This investigation provided us with an initial point for developing novel anticancer agents as dual inhibitors of PLK1 and BRD4.
Collapse
Affiliation(s)
- Jiuyu Liu
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, Liaoning 110016, China
| | - Jingxuan Huang
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, Liaoning 110016, China
| | - Kang Wang
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, Liaoning 110016, China
| | - Yuan Li
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, Liaoning 110016, China
| | - Chunting Li
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, Liaoning 110016, China
| | - Yanli Zhu
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, Liaoning 110016, China
| | - Xinzi He
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, Liaoning 110016, China
| | - Yating Zhang
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, Liaoning 110016, China
| | - Yanfang Zhao
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, Liaoning 110016, China
| | - Changliang Hu
- 3D BioOptima, 1338 Wuzhong Avenue, Suzhou 215104, China
| | - Zhiguo Xi
- 3D BioOptima, 1338 Wuzhong Avenue, Suzhou 215104, China
| | - Minghui Tong
- 3D BioOptima, 1338 Wuzhong Avenue, Suzhou 215104, China
| | - Zhiwei Li
- School of Medicine and Health, Yancheng Polytechnic College, 285 Jiefang South Road, Yancheng, Jiangsu 224005, China
| | - Ping Gong
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, Liaoning 110016, China.
| | - Yunlei Hou
- School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, Liaoning 110016, China.
| |
Collapse
|
3
|
Liu Q, Luo Y, Shi J, Wu Z, Wang Q. Synergistic detoxification by combined reagents and safe filling utilization of cyanide tailings. CHEMOSPHERE 2023; 312:137157. [PMID: 36368542 DOI: 10.1016/j.chemosphere.2022.137157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2022] [Revised: 10/12/2022] [Accepted: 11/04/2022] [Indexed: 06/16/2023]
Abstract
Cyanide tailings are the major hazardous wastes generated in the production process of the gold industry, which not only contain highly toxic cyanide, but also contain heavy metals with recycling value and other substances suitable for building materials or filling. These tailings are in urgent need of purification treatment and safe utilization. In this study, the impacts of treatment methods, types and combinations of reagents on decyanation effect were researched. Gold in cyanide tailings was recovered by flotation, and flotation tailings were used for filling after identifying the properties of solid waste. Results are as follows: (1) INCO method and 5 reagents (sodium sulfite, sodium persulfate, copper sulfate, ferrous sulfate and zinc sulfate) were selected for synergistic decyanation treatment, and cyanide concents in slurry and leaching solution were decreased to the minimum. (2) The gold recovery rate of the tailings through flotation was increased by 27.8% than without detoxification. (3) Flotation tailings were identified as general industrial solid wastes by leaching toxicity and toxic substance content analysis. (4) As filling aggregate, under the conditions of slurry concentration of 63% and cement-sand ratio of 1:6, the strength filling body of flotation tailings reached 1.32 Mpa after 28 days of maintenance. (5) This process and combined reagents were applied to engineering. The cyanide content in the leaching solution and the flotation recovery rate of gold were kept below 0.2 mg/L and above 60% respectively, and the strength of the filling body was stable to meet the requirements of underground filling.
Collapse
Affiliation(s)
- Qiang Liu
- Department of Environmental Engineering, College of Environmental and Resource Science, Zhejiang University, Hangzhou, 310058, China; State Key of Comprehensive Utilization of Low-grade Refractory Gold Ores, Shanghang, 364200, China; Xiamen Zijin Mining & Metallurgy Technology Co., Lid., Xiamen, 361101, China
| | - Yating Luo
- Department of Environmental Engineering, College of Environmental and Resource Science, Zhejiang University, Hangzhou, 310058, China
| | - Jiyan Shi
- Department of Environmental Engineering, College of Environmental and Resource Science, Zhejiang University, Hangzhou, 310058, China.
| | - Zengling Wu
- State Key of Comprehensive Utilization of Low-grade Refractory Gold Ores, Shanghang, 364200, China; Xiamen Zijin Mining & Metallurgy Technology Co., Lid., Xiamen, 361101, China
| | - Qiankun Wang
- State Key of Comprehensive Utilization of Low-grade Refractory Gold Ores, Shanghang, 364200, China; Xiamen Zijin Mining & Metallurgy Technology Co., Lid., Xiamen, 361101, China
| |
Collapse
|
4
|
Surya Prakash Rao H, Prabhakaran J, Kaloor U. Facile and High‐Yielding Synthesis of C(3)‐Aminoisoindolinones Under Metal Catalyst‐Free Conditions. ChemistrySelect 2022. [DOI: 10.1002/slct.202104421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- H. Surya Prakash Rao
- Department of Chemistry Pondicherry University Puducherry 605 014 India
- Vasista Pharma Chem Pvt Limited, Gajularamaram Hyderabad 500 090 India
| | - J. Prabhakaran
- Department of Chemistry Pondicherry University Puducherry 605 014 India
| | - Uthara Kaloor
- Department of Chemistry Pondicherry University Puducherry 605 014 India
| |
Collapse
|
5
|
Lai H, Xu J, Lin J, Su B, Zha D. Chemo-selective control of Ritter-type reaction by coordinatively unsaturated inorganic salt hydrates. Org Chem Front 2022. [DOI: 10.1039/d1qo01832a] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
We used a readily available water source, MgSO4·2H2O, to realize the control of the chemo-selectivity of the Ritter-type reaction efficiently.
Collapse
Affiliation(s)
- Huifang Lai
- Department of Medicinal Chemistry, School of Pharmacy, Fujian Medical University, Fuzhou 350004, Fujian Province, China
| | - Jiexin Xu
- Department of Medicinal Chemistry, School of Pharmacy, Fujian Medical University, Fuzhou 350004, Fujian Province, China
| | - Jin Lin
- Department of Medicinal Chemistry, School of Pharmacy, Fujian Medical University, Fuzhou 350004, Fujian Province, China
| | - Biling Su
- Department of Medicinal Chemistry, School of Pharmacy, Fujian Medical University, Fuzhou 350004, Fujian Province, China
| | - Daijun Zha
- Department of Medicinal Chemistry, School of Pharmacy, Fujian Medical University, Fuzhou 350004, Fujian Province, China
- Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, Fujian Medical University, China
| |
Collapse
|
6
|
Abstract
Abstract
Collapse
|